On October 6, 2025 Biomed Valley Discoveries (BVD), a clinical-stage biotechnology company guided by its founders’ intent of bringing hope for life to patients, reported that results from a Phase 1b study investigating the safety and synergistic effects of intratumoral injection of Clostridium novyi-NT in combination with pembrolizumab in patients with advanced solid tumors were recently published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR) (Free AACR Whitepaper). Conducted in collaboration with researchers at The University of Texas MD Anderson Cancer Center, the Phase 1b study demonstrated an overall objective response rate (ORR) of 25% (n=4) among patients with various advanced solid tumor malignancies. These findings build upon results from an earlier Phase 1 study that demonstrated encouraging safety, tolerability, and anti-tumor results with CNV-NT monotherapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
BVD is researching Clostridium novyi-NT (non-toxic) (CNV-NT/BVD-550) – an attenuated form of the Clostridium novyi, or C. novyi, bacteria – as a modality to target the necrotic cores of tumors and unleash a powerful tumor-destroying attack. C. novyi is a spore-forming, anaerobic bacterium that can only thrive in hypoxic regions (regions that lack oxygen) such as the necrotic core of a tumor. The consequence of germination and growth of CNV-NT results in direct tumor destruction as well as activation of the host immune system.
"A cancer-fighting presence in the necrotic cores of tumors is critical because current standard-of-care therapies typically do not destroy all cancer cells within these regions. This may, in turn, contribute to cancer’s growth and progression. CNV-NT can uniquely target and destroy typically difficult-to-access necrotic cores in tumors," said Brent Kreider, Ph.D., President of BVD and a co-author of the publication. "The powerful anti-cancer benefit of bacteria-based therapy was demonstrated well over a century ago. With the publication of these new data, we are excited to reinforce the potential of this approach to address critical unmet needs of cancer patients who may have few other treatment options."
"The innate immune response we observed with CNV-NT in the Phase 1 monotherapy trial suggested that pairing this therapeutic modality with an immunotherapy like pembrolizumab could amplify and enhance the durability of its cancer-fighting attack. The encouraging early data on this combination study support this hypothesis," said Sarina Piha-Paul, M.D., professor, of Investigational Cancer Therapeutics at MD Anderson, and corresponding author of the publication.
Study Design and Results
A total of 16 patients with advanced solid tumors were enrolled in the Phase 1b study. Patients received a single intratumoral injection of C. novyi-NT on day 8 across four dose cohorts (3 × 104 to 100 × 104 spores) with pembrolizumab (200 mg intravenously) every 3 weeks, day 0–24 months.
The combination therapy was generally well tolerated, with one grade 3 dose-limiting toxicity of abscess formation. The remainder of treatment-related adverse events, observed in ≥10% of patients, were grade 1 or 2 and included injection site reaction, pyrexia, pruritus, leukopenia, and anemia. The maximum tolerated dose was determined to be 200 mg pembrolizumab every 3 weeks and a single dose of 100 × 104 C.novyi-NT spores.
The confirmed ORR of 25% was observed among four patients with various tumor types, including nonkeratinizing undifferentiated nasopharyngeal squamous carcinoma, human papilloma virus–positive squamous cell carcinoma of the base of the tongue, vulvar melanoma, and chordoma (a rare cancer that originates in the bones of the spine or the skull). Among these patient responders, three partial responses and one complete response were observed, with a median duration of response of 10.93 months. Stable disease was observed in 69% of patients.
"With promising therapeutic viability data now in hand for CNV-NT as both a monotherapy and a combination therapy, we are evaluating possible partnerships for the next stage of development," said Dr. Kreider.
(Press release, BioMed Valley Discoveries, OCT 6, 2025, View Source [SID1234665997])